Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
14.62
+1.31 (9.84%)
At close: Oct 9, 2026, 4:00 PM EDT
14.60
-0.02 (-0.14%)
After-hours: Oct 9, 2026, 7:57 PM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year. That makes Iovance Biotherapeutics the 15,093rd largest employer in the world and 2,199th in the United States.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$333,302
Profits / Employee
-$296,941
Market Cap
6.62B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| Mirum Pharmaceuticals | 433 |
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 315 |
| Praxis Precision Medicines | 168 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
| Erasca | 103 |
IOVA News
- 3 days ago - Iovance Biotherapeutics price target raised to $11 from $6 at Baird - TheFly
- 10 days ago - Iovance Biotherapeutics appoints Berkowitz as CMO - TheFly
- 10 days ago - Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 11 days ago - Iovance Biotherapeutics price target raised to $18 from $14 at Wells Fargo - TheFly
- 12 days ago - Iovance Biotherapeutics rises 27.8% - TheFly
- 12 days ago - Iovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright - TheFly
- 12 days ago - Iovance Biotherapeutics rises 25.9% - TheFly
- 12 days ago - Iovance Biotherapeutics raises FY26 revenue view to $410M-$420M - TheFly